PR··Consumer Staples
CVS Health study highlights GLP-1 benefits and the affordability challenge
Real-world analysis finds better outcomes and lower medical spending, but current prices limit the full economic value
Press Releases
Delayed 55sFastest customizable press release feed in the world.
Signed out · Sign up for real-time
Updates arrive automatically.
CVS Health study highlights GLP-1 benefits and the affordability challenge Lexeo Therapeutics to Report Third Quarter 2026 Financial Results and Provide LX2020 Business Update on November 16, 2026 PR··Health CareLexeo Therapeutics to Report Third Quarter 2026 Financial Results and Provide LX2020 Business Update on November 16, 2026
Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced it will report third quarter 2026 financial results and provide a business update on the ongoing HEROIC-PKP2 Phase I/II clinical trial of LX2020 for the treatment of PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM) on Monday, November 16, 2026. A webcast will be held at 8:00 AM ET on November 16, 2026. Analysts and investors can access the live event through the Events & Presentations page in the Investors section of Lexeo’s website. A replay will be available following the call. About LX2020 LX20
Cocrystal Pharma Provides Business Update and Reports Third Quarter 2026 Financial Results PR··Health CareCocrystal Pharma Provides Business Update and Reports Third Quarter 2026 Financial Results
Completed dosing in Phase 1b challenge study of CDI-988 for norovirus prevention and treatment with no serious adverse events reportedPreliminary efficacy results expected near the end of 2026 Closed $5 million private placement with OPKO HealthAppointed antiviral drug development leader Carol
Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application PR··Health CareSummit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application
Complete Response Letter Received from FDA for BLA Application Based on HARMONi Study Summit Therapeutics Inc. (NASDAQ:SMMT) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for ivonescimab in combination with platinum-containing chemotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), who have received prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy. Ivonescimab is a novel PD-1 x VEGF bispecific antibody. "As a cancer survivor, I understand firsthand how important it is for patients
BA Investors Who Received Shares of The Boeing Company in Connection to Its Merger with Spirit AeroSystems Can Join Fraud Investigation with SBS Law PR··IndustrialsBA Investors Who Received Shares of The Boeing Company in Connection to Its Merger with Spirit AeroSystems Can Join Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of The Boeing Company ("Boeing" or "the Company") (NYSE: BA) who received shares in connection with its December 2025 merger ("the Merger") with Spirit AeroSystems Holdings, Inc. ("Spirit") (NYSE:SPR) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Following the Merger with Spirit, shares of Boeing have declined significantly. If you are a shareholder who suffered a loss, cli
Hot Wheels Crowns 2026 Legends Tour Winner Following Global Search Across 19 Countries PR··Consumer DiscretionaryHot Wheels Crowns 2026 Legends Tour Winner Following Global Search Across 19 Countries
A radically reimagined 1979 Chevrolet El Camino takes the top prize in the 2026 Hot Wheels Legends Tour Presented by Mobil 1 The fan-built car will be transformed into an official 1:64-scale Hot Wheels die-cast sold worldwide Tampa custom-car builder Matt McEntegart brings the global title back to the U.S. for the first time since 2022 Photos of the 2026 Hot Wheels Legends Tour winner and runners-up can be found HERE. Mattel, Inc. (NASDAQ:MAT), a leading global play and family entertainment company and owner of one of the world’s most iconic brand portfolios, today announced the 2026 winner of the Hot Wheels™ Legends Tour presented by Mobil 1, the world’s largest traveling car
Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale PR··Health CareLilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale
Phase 2 results showed EloraTZP, an investigational combination of eloralintide and tirzepatide, delivered substantial weight loss and A1C improvements in participants with obesity and type 2 diabetesResults from TRIUMPH-1, TRIUMPH-2 and TRIUMPH-4 demonstrated retatrutide, an investigational triple agonist, reduced obstructive sleep apnea severity and knee osteoarthritis pain in adults with obesityPeople reported Foundayo was simple and easy to use in a new real-world evidence study, while patient-reported outcomes showed that participants treated with eloralintide reported reductions in food noise, food cravings and alcohol consumption
Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting PR··Health CareAmylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
LUCIDITY met its prespecified primary endpoint; avexitide reduced the composite Level 2/3 hypoglycemic event rate by 55% compared to placebo (p=0.000003) Avexitide showed consistent, highly statistically significant reductions across all prespecified, multiplicity-controlled secondary event-rate endpoints vs. placebo Avexitide was generally well-tolerated with a favorable safety profile; adverse events during the double-blind treatment period were generally mild to moderate in severity Company to host an in-person and webcast investor KOL event tomorrow, November 15, at 11:45 AM ET Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") will present the res
Rocket Lab Hits 100 Electron Launches, Fastest Commercial Rocket to Reach the Milestone PR··IndustrialsRocket Lab Hits 100 Electron Launches, Fastest Commercial Rocket to Reach the Milestone
Rocket Lab Corporation (NASDAQ:RKLB), a global leader in launch services and space systems, today announced mission success for its 100th Electron launch, setting a new record for reaching 100 launches faster than any other commercially developed rocket. "The Mountain God Rises" mission launched from Rocket Lab Launch Complex 1 in New Zealand at 6:30 p.m. on November 14, 2026, deploying the YAMATSUMI-II synthetic aperture radar (SAR) Earth-imaging satellite to a 575km low Earth orbit for the Institute for Q-shu Pioneers of Space, Inc. (iQPS). This mission marks Rocket Lab’s 11th Electron launch for iQPS with 100% mission success since
CORRECTION: Axe Compute to Host Q3 2026 Financial Results Conference Call PR··Health CareCORRECTION: Axe Compute to Host Q3 2026 Financial Results Conference Call
In a release issued under the same headline on November 11th by Axe Compute (NASDAQ:AGPU), please note that the date of the conference call in the first paragraph was incorrect. It should have been November 17, 2026, instead of November 16, 2026. The corrected release follows: Axe Compute (NASDAQ:AGPU), a neocloud AI infrastructure company delivering dedicated, bare-metal GPU compute and large-scale AI factory build-outs at global scale, today announced it will hold a conference call and webcast to review financial results for the third quarter ended September 30, 2026, before market open on Tuesday, November 17, 2026. Speakers on the call will be
Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China’s 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products PR··Health CareZai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China’s 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products
Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)), an innovation-driven, global biopharma company, today announced that five of its commercial medicines in China have been included in the country’s 2026 National Reimbursement Drug List (NRDL). The update includes two first-time listings, expanding patient access to treatments for gMG and schizophrenia, and three renewals, which maintain access across oncology and infectious disease. Zai Lab Products Newly Added or Renewed in 2026 NRDL: First-time listings: VYVGART Hytrulo® (efgartigimod alfa, subcutaneous injection): for the treatment of adult patients with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (
Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR··IndustrialsQuantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced that the Compensation Committee of Quantum-Si’s Board of Directors has granted 495,335 restricted stock units ("RSUs") to new employees under the Company’s previously adopted Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan, as amended (the "2023 Inducement Plan"). The RSUs were granted as an inducement material to the new employees becoming an employee of Quantum-Si in accordance with Nasdaq Listing Rule 5635(c)(4). The 2023 Inducement Plan i
Cohen & Steers Announces Changes to Realty Indexes PR··FinanceCohen & Steers Announces Changes to Realty Indexes
Cohen & Steers, Inc. (NYSE:CNS) announced today pending changes to its Realty Majors Portfolio Index (RMP), Global Realty Majors Portfolio Index (GRM) and International Realty Majors Portfolio Index (IRP), effective as of the close of business on November 20, 2026. Cohen & Steers Realty Majors Portfolio Index (RMP)Added component (symbol)Removed component (symbol)American Healthcare REIT, Inc. (AHR.US)VICI Properties, Inc. (VICI.US)Cohen & Steers Global Realty Majors Portfolio Index (GRM)Added component (symbol)Removed component (symbol)American Healthcare REIT, Inc. (AHR.US)VICI Properties, Inc. (VICI.US)Great Portland Estates plc (GPE.LN)Derwent Lond
/C O R R E C T I O N - BTQ Technologies Corp./ PR··Technology/C O R R E C T I O N - BTQ Technologies Corp./
In the news release, BTQ Technologies to Host Live Webinar on Q3 2026 Financial Results and General Corporate Update, issued Nov. 13, 2026 by BTQ Technologies Corp. over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows: BTQ Technologies to Host Live Webinar on Q3 2026 Financial
Dana Announces Pricing, Expiration and Results of Tender Offers for Any and All of its Outstanding 4.250% Senior Notes due 2030 and 4.500% Senior Notes due 2032 PR··Consumer DiscretionaryDana Announces Pricing, Expiration and Results of Tender Offers for Any and All of its Outstanding 4.250% Senior Notes due 2030 and 4.500% Senior Notes due 2032
Dana Incorporated (NYSE:DAN) ("Dana" or the "Company") announced today the pricing, expiration and results of its tender offers to purchase for cash any and all of its outstanding 4.250% Senior Notes due 2030 (the "2030 Notes") and 4.500% Senior Notes due 2032 (the "2032 Notes" and, together with the 2030 Notes, the "Notes"). The tender offers (each, an "Offer" and, together, the "Offers") were made pursuant to the Offer to Purchase, dated November 6, 2026 (the "Offer to Purchase"). The Offers expired at 5:00 p.m., New York City time, on November 13, 2026 (the "Expiration Date"). Acco
Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer PR··Health CarePerioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer
Based on VOLGA Phase III trial data which showed a 49% reduction in risk of recurrence and a 42% reduction in risk of death, with a manageable safety profile Approval reinforces potential of IMFINZI as an immunotherapy backbone across muscle-invasive and non-muscle-invasive bladder cancer AstraZeneca’s IMFINZI® (durvalumab) in combination with enfortumab vedotin-ejfv (EV) as neoadjuvant treatment, followed by IMFINZI monotherapy as adjuvant treatment after radical cystectomy (surgery to remove the bladder), has been approved in the US for the treatment of adult patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or have refused cisplatin-based chemotherapy. T
Bloom Energy Supports Louisiana Disaster Relief Ahead of Texas-LSU Matchup PR··EnergyBloom Energy Supports Louisiana Disaster Relief Ahead of Texas-LSU Matchup
As Baton Rouge gets ready for the Texas-LSU matchup, Bloom Energy is joining the community off the field to support two organizations making a difference for families across Louisiana. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113756487/en/ On Friday, Bloom Energy visited Baton Rouge Fire Station 12 to recognize the work of the Baton Rouge Area Foundation and Civic Collaborative Foundation, two organizations helping strengthen communities and support Louisianans in times of need. As part of the event, Bloom Energy presented each organization with a $10,000 donation. "Keeping communities safe depends on the people and o
Chime Financial Set to Join S&P MidCap 400 PR··FinanceChime Financial Set to Join S&P MidCap 400
Chime Financial Inc. (NASD: CHYM) will replace NorthWestern Energy Group Inc. (NASD: NWE) in the S&P MidCap 400 effective prior to the opening of trading on Wednesday, November 18. S&P MidCap 400 constituent Black Hills Corp. (NYSE:BKH) is acquiring NorthWestern Energy Group in a deal expected to be completed today. Post-merger, the combined company will remain in the S&P MidCap 400 and will be renamed Bright Horizon Energy Corp. (NYSE:HZN). Following is a summary of the changes that will take place prior to the open of trading on the effective date:Effective DateIndex Name ActionCompany NameTickerGICS SectorNovember 18, 2026 S&P MidCap 400
Service Properties Trust Receives Statement of Support from Shareholder Flat Footed LLC PR··Real EstateService Properties Trust Receives Statement of Support from Shareholder Flat Footed LLC
Service Properties Trust (NASDAQ:SVC) ("SVC" or the "Company") today announced that Flat Footed LLC ("Flat Footed"), an SVC institutional shareholder, has expressed support for the plan announced earlier today by SVC’s Board of Trustees to transition SVC into a pure-play triple net lease REIT. Marc Andersen, Co-Founder and Managing Member of Flat Footed LLC, made the following statement: "Given the capital recently deployed into the retained hotel portfolio and the commitment of SVC’s Board to convert the Company into a triple net lease REIT over the next two years, Flat Footed supports SVC’s decision to monetize the hotel portfolio at a pace that allows for maximum value realization. O
Organigram Provides NASDAQ Listing Update PR··Health CareOrganigram Provides NASDAQ Listing Update
The Notification has no immediate effect on the listing or trading of the Company's common shares on the Nasdaq Global Select Market. Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI) (the "Company" or "Organigram"), Canada's #1 cannabis company by market share¹ and a growing global cannabis platform, today announced that on November 11, 2026, it received notification (the "Notification") from The Nasdaq Stock Market LLC ("Nasdaq") that it is not in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Select Market. The Notification was issued because the closing bid price of the Company's common shares was below US$